Home PD, et al. - The efficacy and safety of MK-1293 insulin glargine (Mk-Gla; 100 U/mL) with originator insulin glargine, Lantus (Sa-Gla), in people with type 1 diabetes mellitus (T1DM) were compared in this phase 3, randomized, active-controlled, open-label, 52-week study. Five hundred eight people with T1DM (HbA1c ≤11.0%; 97 mmol/mol) taking basal and prandial insulin were recruited. According to the findings obtained, Mk-Gla and Sa-Gla showed similar efficacy and safety over 52 weeks in people with T1DM.